

# READY-TO-USE PANELS FOR ONCOLOGY

CELEMICS PRODUCTS & SERVICES 2021

BRCA 1/2 Panel  
OncoRisk Panel  
CancerScreen Panel - Core / 50 / 100 / 400  
CancerMaster Panel




# BRCA 1/2 Panel

Germline and Somatic Cancer

## PANEL PERFORMANCE

### 1. Superior Panel Performance Compared to Competitor Product



## KEY FEATURES

- |  |  |
|--|--|
| <p><b>1. Targets the whole CDS (+/- 40) and promoter regions of BRCA 1/2 with high specificity</b></p> | <p>Target regions not only covering the CDS regions but expanded to +40 and -40 of CDS to detect splicing site variants</p> <p>Probes specifically designed for detecting deletion, duplication, and large rearrangement</p> |
| <p><b>2. Compatible with a variety of sample types</b></p>   | <p>No compromise on panel performance even with of using DNA from challenging specimen types such as blood and FFPE</p>  |
| <p><b>3. Market-leading panel performance in uniformity and coverage</b></p>                           | <p>Designed to target whole exon regions of BRCA 1, 2 gene with 100% coverage (RefSeq) and validated to yield 100% coverage</p>  |


## SPECIFICATION

|                         |  |
|-------------------------|--|
| Gene count*             | BRCA 1/2 genes   |
| Covered region          | Whole CDS (+/- 40bp), UTR, Promoter  |
| Target size             | 23 kb  |
| Mutation type           | SNV, Indel, CNV  |
| Sample type (amount)    | Blood (> 50 ng of fragmented DNA), FFPE  |
| Platform                | All sequencers from Illumina, Thermo Fisher, MGI, PacBio, and Oxford Nanopore          |
| Sensitivity             | > 95% for all variant types at 5% VAF  |
| Specificity             | 99.9% (SNV), 99.5% (Indel)   |
| Bioinformatics pipeline | Primary, Secondary and Tertiary analysis result (FASTQ to VCF, VCF to Clinical report) |

\* Gene Add-on Service: Genes can be added or removed by customer demand

### 2. SNV, CNV Analysis

BRCA1, S1556G & S1389S / BRCA2, N372H & L152IL / BRCA1 CNV plot



## PACKAGE COMPOSITION

| Package name      | Compositions               |                    |   | Package option           | Options         |                     |
|-------------------|----------------------------|--------------------|---|--------------------------|-----------------|---------------------|
| Target Enrichment | Target capture Probe       |                    | - | Pooling method           | Single Reaction | Pre-capture Pooling |
| Standard          | Target Enrichment reagents | Library prep kit   | - | Library Preparation kits | Standard Kit    | EP-kit              |
| All-In-One        |                            | Beads / Polymerase |   | Hybridization Enhancer   | Included        | Not included        |



# OncoRisk Panel

Hereditary Cancer  
(Germline cancer risk)

## KEY FEATURES

|   |   |
|---|---|
| 1. Comprehensive analysis of oncogenes                        | Analyze 31 oncogenes associated with inherited cancer and precisely selected from contract research organizations and numerous research studies |
| 2. Robust bioinformatics system for large deletion analysis   | Receive bioinformatics results for large deletion analysis provided by Celemics proprietary bioinformatics analysis system                      |
| 3. Used for Homologous Recombination Deficiency (HRD) testing | Provides information for HDR grade computation to aid precision medicine for tumor treatment  |

## SPECIFICATION

|                         |  |
|-------------------------|--|
| Gene count*             | 31 genes   |
| Covered region          | Whole CDS  |
| Target size             | 96 kb  |
| Mutation type           | SNV, Indel, CNV, Rearrangement   |
| Sample type (amount)    | Blood (> 50 ng of fragmented DNA), FFPE  |
| Platform                | All sequencers from Illumina, Thermo Fisher, MGI, PacBio, and Oxford Nanopore          |
| Sensitivity             | > 95% for all variant types at 5% VAF  |
| Specificity             | 99.90% (SNV), 99.50% (Indel)   |
| Bioinformatics pipeline | Primary, Secondary and Tertiary analysis result (FASTQ to VCF, VCF to Clinical report) |

\* Gene Add-on Service: Genes can be added or removed by customer demand

## GENE LIST

|                |      |        |       |      |        |       |       |       |       |      |        |        |        |
|----------------|------|--------|-------|------|--------|-------|-------|-------|-------|------|--------|--------|--------|
| OncoRisk Panel | APC  | ATM    | BARD1 | BLM  | BMPRIA | BRCA1 | BRCA2 | BRIP1 | CDHI  | CDK4 | CDKN2A | CHEK2  | EPCAM  |
|                | MLH1 | MRE11A | MSH2  | MSH6 | MUTYH  | NBN   | PALB2 | PMS2  | PRSS1 | PTEN | RAD50  | RAD51C | RAD51D |
|                | SLX4 | SMAD4  | STK11 | TP53 | VHL    |       |       |       |       |      |        |        |        |


## PANEL PERFORMANCE

### 1. SNV Analysis Example

| Gene   | Mutation Type | Amino Acid Change | Total Depth | REF Depth | ALT Depth | Variant Allele Frequency |
|--------|---------------|-------------------|-------------|-----------|-----------|--------------------------|
| APC    | SYN           | p.S1738S          | 1008        | 590       | 415       | 41.17%                   |
| ATM    | Non-SYN       | p.D1853N          | 417         | 200       | 217       | 52.04%                   |
| BARD1  | Non-SYN       | p.R658C           | 829         | 435       | 394       | 47.53%                   |
| BMPRIA | Non-SYN       | p.P2T             | 621         | 309       | 311       | 50.08%                   |
| BRCA1  | SYN           | p.S1389S          | 802         | 460       | 342       | 42.64%                   |
| BRCA2  | SYN           | p.V2171V          | 1026        | 0         | 1026      | 100%                     |
| BRIP1  | SYN           | p.Y1137Y          | 844         | 3         | 840       | 99.53%                   |
| PMS2   | Non-SYN       | K54E              | 686         | 0         | 646       | 100%                     |
| PRSS1  | SYN           | p.N246            | 921         | 0         | 921       | 100%                     |
| RAD51D | Non-SYN       | p.L152L           | 971         | 0         | 971       | 100%                     |

### 2. CNV Analysis Example

Higher sequencing depths in the target regions, enabling accurate CNV analysis



## PACKAGE COMPOSITION

| Package name      | Compositions                           | Package option           | Options                                |
|-------------------|--|--------------------------|--|
| Target Enrichment | Target capture Probe                   | Pooling method           | Single Reaction    Pre-capture Pooling |
| Standard          | Target Enrichment reagents             | Library Preparation kits | Standard Kit    EP-kit                 |
| All-In-One        | Library prep kit<br>Beads / Polymerase | Hybridization Enhancer   | Included    Not included               |



# CancerScreen Panel

**Core/50/100/400**

Somatic Cancer

## KEY FEATURES

- |                                     |  |
|-------------------------------------|--|
| 1. Optimized panel for solid cancer | Assess DNA, RNA, and the whole CDS regions (RefSeq) of up to 407 genes and rearrangement regions associated with solid cancer                                |
| 2. High sensitivity and specificity | Detect low-frequency and rare variants with high sequencing depths<br>Capture the GC rich and homologous regions with Celemics proprietary design technology |
| 3. Cost-effective sequencing        | Lower sequencing costs for 3 Gb sequencing amount compared to competitor product   |
| 4. Assess all variant types         | Detect all mutation types including SNV, Indel, Large Indel, CNV, Rearrangement, MSI, and TMB in a single assay  |

## SPECIFICATION


|                         |  |
|-------------------------|--|
| Gene count*             | 13 / 54 / 99 / 407 genes   |
| Target size             | 61 / 197 / 299 / 1,123 kb + Rearrangement  |
| Mutation type           | SNV, Indel, CNV, Rearrangement, MSI, TMB   |
| Sample type             | FFPE, frozen tissue, cfDNA, RNA  |
| Platform                | All sequencers from Illumina, Thermo Fisher, MGI, PacBio, and Oxford Nanopore          |
| Bioinformatics pipeline | Primary, Secondary and Tertiary analysis result (FASTQ to VCF, VCF to clinical report) |

\* Gene Add-on Service: Genes can be added or removed by customer demand

## PANEL PERFORMANCE


### Performance Comparison with Competitor Product

Higher on-target ratio, uniformity, and coverage at 100X compared to competitor product over the target regions including exons and introns (Compared with the same sequencing depth)



### Performance Comparison over GC-rich Regions

Higher uniform read depths over GC-rich regions compared to competitor product (Compared with the same sequencing depth)



## PACKAGE COMPOSITION

| Package name      | Compositions               |                    | Package option           | Options         |                     |
|-------------------|----------------------------|--------------------|--------------------------|-----------------|---------------------|
| Target Enrichment | Target capture Probe       | -                  | Pooling method           | Single Reaction | Pre-capture Pooling |
| Standard          | Target Enrichment reagents | Library prep kit   | Library Preparation kits | Standard Kit    | EP-kit              |
| All-In-One        |                            | Beads / Polymerase | Hybridization Enhancer   | Included        | Not included        |

# CancerScreen Panel Core

## DESCRIPTION

CancerScreen Panel Core is an NGS assay designed to detect all types of variants in 13 genes associated with somatic cancer. Targeting the selected genes with high sensitivity and specificity enables saving cost and effort. The report consists of the primary, secondary, and tertiary results for the In-depth understanding and interpretation of sequencing data.

## GENE LIST

|                         |            |     |      |      |       |      |     |      |        |            |             |       |      |
|-------------------------|------------|-----|------|------|-------|------|-----|------|--------|------------|-------------|-------|------|
| CancerScreen Panel Core | <b>ALK</b> | APC | BRAF | EGFR | ERBB2 | KRAS | MET | NRAS | PIK3CA | <b>RET</b> | <b>ROS1</b> | SMAD4 | TP53 |
|-------------------------|------------|-----|------|------|-------|------|-----|------|--------|------------|-------------|-------|------|

\* Genes in bold indicate fusion analysis

# CancerScreen Panel 50

## DESCRIPTION

CancerScreen Panel 50 is an expanded NGS assay designed to detect all types of variants in over 50 genes associated with somatic cancer. Targeting the selected genes with high sensitivity and specificity enables saving cost and effort. The report consists of the primary, secondary, and tertiary results for the In-depth understanding and interpretation of sequencing data.

## GENE LIST

|                       |        |              |            |        |       |      |        |       |            |             |       |        |        |
|-----------------------|--------|--------------|------------|--------|-------|------|--------|-------|------------|-------------|-------|--------|--------|
| CancerScreen Panel 50 | ABL1   | AKT1         | <b>ALK</b> | APC    | ATM   | BRAF | BRCA1  | BRCA2 | CDH1       | CDK4        | CDK6  | CDKN2A | CSF1R  |
|                       | CTNNB1 | DDR2         | EGFR       | ERBB2  | ERBB4 | ESR1 | FGFR1  | FGFR2 | FGFR3      | GNAI1       | GNAQ  | GNAS   | HRAS   |
|                       | IDH1   | IDH2         | JAK2       | KDR    | KIT   | KRAS | MAP2K1 | MET   | MLH1       | MTOR        | MYC   | MYCN   | NOTCH1 |
|                       | NRAS   | <b>NTRK1</b> | PDGFRA     | PIK3CA | PTCH1 | PTEN | PTPN11 | RBI   | <b>RET</b> | <b>ROS1</b> | SMAD4 | SMO    | SRC    |
|                       | STK11  | TP53         |            |        |       |      |        |       |            |             |       |        |        |

\* Genes in bold indicate fusion analysis

# CancerScreen Panel 100

## DESCRIPTION

CancerScreen Panel 100 is an NGS assay for the comprehensive analysis of around 100 genes associated with somatic cancer. All types of variants are detected with high sensitivity and specificity. The report consists of the primary, secondary, and tertiary results for the In-depth understanding and interpretation of sequencing data.

## GENE LIST

|                        |       |        |        |        |       |        |        |        |        |        |        |        |         |
|------------------------|-------|--------|--------|--------|-------|--------|--------|--------|--------|--------|--------|--------|---------|
| CancerScreen Panel 100 | ABL1  | AKT1   | AKT2   | AKT3   | ALK   | APC    | ARID1A | ARID1B | ARID2  | ATM    | ATRX   | AURKA  | AURKB   |
|                        | BARD1 | BCL2   | BLM    | BMPRIA | BRAF  | BRCA1  | BRCA2  | BRIPI  | CDH1   | CDK4   | CDK6   | CDKN2A | CHEK2   |
|                        | CSF1R | CTNNB1 | DDR2   | EGFR   | EPCAM | EPHB4  | ERBB2  | ERBB3  | ERBB4  | EZH2   | FBXW7  | FGFR1  | FGFR2   |
|                        | FGFR3 | FLT3   | GNAI1  | GNAQ   | GNAS  | HNFLA  | HRAS   | IDH1   | IDH2   | IGF1R  | ITK    | JAK1   | JAK2    |
|                        | JAK3  | KDR    | KIT    | KRAS   | MDM2  | MET    | MLH1   | MPL    | MRE11  | MSH2   | MSH6   | MTOR   | MUTYH   |
|                        | NBN   | NF1    | NOTCH1 | NPM1   | NRAS  | NTRK1  | PALB2  | PDOFRA | PDGFRB | PIK3CA | PIK3R1 | PMS2   | PRSS1   |
|                        | PTCH1 | PTCH2  | PTEN   | PTPN11 | RAD50 | RAD51C | RAD51D | RBI    | RET    | ROS1   | SLX4   | SMAD4  | SMARCB1 |
|                        | SMO   | SRC    | STK11  | SYK    | TERT  | TOPI1  | TP53   | VHL    |        |        |        |        |         |

# CancerScreen Panel 400

## DESCRIPTION

CancerScreen Panel Core is an NGS assay designed to detect all types of variants in over 400 genes associated with somatic cancer. Targeting the selected genes with high sensitivity and specificity enables saving cost and effort. The report consists of the primary, secondary, and tertiary results for the In-depth understanding and interpretation of sequencing data.



# CancerScreen Panel

400

## GENE LIST

CancerScreen Panel 400

|        |         |          |          |         |         |         |        |        |         |        |         |         |
|--------|---------|----------|----------|---------|---------|---------|--------|--------|---------|--------|---------|---------|
| ABL1   | ABL2    | ADGRA2   | AKT1     | AKT2    | AKT3    | ALK     | AMER1  | APC    | APCDD1  | APEX1  | APOB    | APOBEC1 |
| AR     | ARAF    | ARFRP1   | ARID1A   | ARID1B  | ARID2   | ASXL1   | ATM    | ATP11B | ATR     | ATRX   | AURKA   | AURKB   |
| AXINI  | AXL     | B2M      | B3GAT1   | BACH1   | BAP1    | BARD1   | BCL2   | BCL6   | BCL9    | BCOR   | BCR     | BIRC2   |
| BIRC3  | BLM     | BRAF     | BRCA1    | BRCA2   | BRD2    | BRD3    | BRD4   | BRIPI  | BTG1    | BTK    | BTLA    | CARD11  |
| CASP5  | CASP8   | CBFB     | CBL      | CDK12   | CDK4    | CDK6    | CDK8   | CDKN1A | CDKN1B  | CDKN2A | CDKN2B  | CDKN2C  |
| CDX2   | CEBPA   | CHD1     | CHD2     | CHD4    | CHEK1   | CHEK2   | CHUK   | CIC    | CRBN    | CREBBP | CRKL    | CRLF2   |
| CSF1R  | CSF2    | CSF2RA   | CSF2RB   | CSNK2A1 | CTCF    | CTLA4   | CTNNA1 | CTNNB1 | CUL3    | CUL4A  | CUL4B   | CXCL10  |
| CXCL11 | CXCL9   | CXCR3    | CYLD     | CYP17A1 | DAXX    | DCUN1D1 | DDR2   | DICER1 | DIS3    | DNMT1  | DNMT3A  | DOCK2   |
| DOTL   | EGFR    | ELMO1    | EML4     | EMSY    | EP300   | EPHA3   | EPHA5  | EPHA6  | EPHA7   | EPHB1  | EPHB4   | EPHB6   |
| ERBB2  | ERBB3   | ERBB4    | ERCC1    | ERCC2   | ERG     | ERRF1   | ESR1   | ETV1   | ETV4    | ETV5   | ETV6    | EWSR1   |
| EYA2   | EZH2    | FANCA    | FANCC    | FANCD2  | FANCE   | FANCF   | FANCG  | FANCI  | FANCL   | FANCM  | FAS     | FAT1    |
| FAT3   | FBXW7   | FGF1     | FGF10    | FGF12   | FGF14   | FGF19   | FGF2   | FGF23  | FGF3    | FGF4   | FGF6    | FGF7    |
| FGFR1  | FGFR2   | FGFR3    | FGFR4    | FH      | FLCN    | FLT1    | FLT3   | FLT4   | FOXA1   | FOXL2  | FOXO3   | FOXP3   |
| FRS2   | FUBP1   | GABRA6   | GAS6     | GATA1   | GATA2   | GATA3   | GATA4  | GATA6  | GJD4    | GLI1   | GNAI1   | GNAI3   |
| GNAQ   | GNAS    | GRIN2A   | GRM3     | GSK3B   | GUCY1A2 | GZMA    | GZMB   | GZMH   | H3F3A   | HGF    | HISTH3B | HNFTA   |
| HOXA3  | HRAS    | HSD3B1   | HSP90AA1 | IDH1    | IDH2    | IDO1    | IDO2   | IFITM1 | IFITM3  | IFNA1  | IFNB1   | IFNG    |
| IGF1   | IGF1R   | IGF2     | IGF2R    | IKBKE   | IKZF1   | IL12A   | IL12B  | IL2    | IL23A   | IL6    | IL7R    | INHBA   |
| INPP4B | INSR    | IRF2     | IRF4     | IRS2    | ITGAE   | ITK     | JAK1   | JAK2   | JAK3    | JUN    | KAT5A   | KDM5A   |
| KDM5C  | KDM6A   | KDR      | KEAP1    | KEL     | KIT     | KLF4    | KLHL6  | KMT2A  | KMT2B   | KMT2C  | KNSTRN  | KRAS    |
| LAG3   | LMO1    | LRP1B    | LRP6     | LTK     | LYN     | LZTR1   | MAGI2  | MAGOH  | MAML1   | MAP2K1 | MAP2K2  | MAP2K4  |
| MAP3K1 | MAP3K13 | MAPK1    | MAX      | MCL1    | MDM2    | MDM4    | MED12  | MEF2B  | MEN1    | MET    | MITF    | MLH1    |
| MPL    | MRE11   | MSH2     | MSH6     | MTOR    | MUTYH   | MYB     | MYC    | MYCL   | MYCN    | MYD88  | MYO18A  | NCOA3   |
| NCOR1  | NF1     | NF2      | NFE2L2   | NFKB1A  | NOTCH1  | NOTCH2  | NOTCH3 | NOTCH4 | NPM1    | NRAS   | NSD1    | NSD3    |
| NTRK1  | NTRK2   | NTRK3    | NUP93    | NUM1    | PAK3    | PAK5    | PALB2  | PARP1  | PARP2   | PARP3  | PARP4   | PAX5    |
| PBRM1  | PDCD1   | PDCD1LG2 | PDGFRA   | PDGFRB  | PDK1    | PGR     | PHF6   | PHLPP2 | PIK3C2B | PIK3C3 | PIK3CA  | PIK3CB  |
| PIK3CG | PIK3R2  | PKHD1    | PLCG1    | PLCG2   | PMS2    | PNP     | PNRC1  | POLD1  | POLE    | PPARG  | PPP2R1A | PRDM1   |
| PREX2  | PRF1    | PRKARIA  | PRKCI    | PRKDC   | PRPF40B | PRSS8   | PTCH1  | PTCH2  | PTEN    | PTK2   | PTPN11  | PTPRC   |
| PTRRD  | QKI     | RAB35    | RAC1     | RAC2    | RAD17   | RAD50   | RAD51  | RAD52  | RAD54L  | RAF1   | RANBP2  | RARA    |
| RBI    | RBM10   | REL      | RET      | RHEB    | RHOA    | RHOB    | RICTOR | ROBO1  | ROBO2   | ROSI   | RPA1    | RPS6KB1 |
| RPTOR  | RUNX1   | RUNX1T1  | RUNX3    | SDHA    | SDHB    | SDHC    | SDHD   | SEMA3A | SEMA3E  | SET    | SETBP1  | SETD2   |
| SF3A1  | SF3B1   | SH2B3    | SKP2     | SLIT2   | SMAD2   | SMAD3   | SMAD4  | SRSF2  | SRSF7   | STAG2  | STAT3   | STAT4   |
| TERT   | TET2    | CD274    | TP53     |         |         |         |        |        |         |        |         |         |



# CancerMaster Panel

Somatic Cancer

## DESCRIPTION

The CancerMaster panel is designed to detect all variant types and the I-O markers, microsatellite instability (MSI) and tumor mutational burden (TMB), which are crucial biomarkers for cancer immunotherapy. For CNV analysis, different cut-off is applied according to the ratio of cancer cells. The panel is also designed to detect Epstein-Barr virus (EBV) and Human Papillomaviruses (HPV) allowing for comprehensive analysis of cancer associated genes.

## KEY FEATURES

|  |  |
|--|--|
| 1. Comprehensive analysis of cancer associated genes | A broad range of targeting elements including somatic variants, IO-signatures (TMB, MSI), EBV and HPV, for clinical diagnoses of different cancer types and precision medicine |
| 2. Extensive validation studies                      | Robust panel performance supported by extensive validation tests with Reference and clinical specimens   |

## SPECIFICATION

|                         |  |
|-------------------------|--|
| Gene count*             | 524 genes  |
| Covered region          | Whole CDS, custom regions of oncogenes, immune response genes, and EBV & HPV viruses   |
| Target size             | 2.5 Mb   |
| Mutation type           | SNV, Indel, CNV, Rearrangement, TMB, MSI, EBV, HPV   |
| Sample type             | FFPE, Fresh frozen tissue (> 50 ng of fragmented DNA)  |
| Platform                | All sequencers from Illumina, Thermo Fisher, MGI, PacBio, and Oxford Nanopore  |
| Bioinformatics pipeline | Primary, Secondary and Tertiary analysis result (FASTQ to VCF, VCF to Clinical report)                                       |
| Publication             | Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and PD-1/PD-L1 Blockade Responses, Hepatology, 2021 |


\*Gene Add-on Service: Genes can be added or removed by customer demand

## GENE LIST

|                |      |      |        |      |       |       |       |       |       |       |     |       |     |
|----------------|------|------|--------|------|-------|-------|-------|-------|-------|-------|-----|-------|-----|
| OncoRisk Panel | ABL1 | ALK  | PDGFRA | ROS1 | FGFR2 | FGFR3 | NTRK1 | NTRK2 | NTRK3 | FGFR1 | MET | PPARG | RET |
|                | AKT3 | BRAF | BRCA1  | EGFR | ERBB2 |       |       |       |       |       |     |       |     |

## PANEL PERFORMANCE


The probes are designed to include the intron regions as well as clinically significant biomarkers. By conducting extensive validation studies with clinical samples, the panel was examined to show its performance with high sensitivity and specificity in detecting the variants in cancer-associated genes.



## ANALYSIS OF EBV & HPV

| EBV (Epstein-Barr Virus)  | HPV (Human Papillomavirus)   |
|---|--|
| <ul style="list-style-type: none"> <li>Related disease – Lymphoma</li> <li>Genes – EBV type 1 (EBNA-2)</li> </ul> | <ul style="list-style-type: none"> <li>Related disease – Cervical cancer</li> <li>Genes – HPV L1 gene<br/>(Analysis of a total of 24 types is possible)</li> </ul> |

Validation for detection of EBV type 1 (EBNA-2) in control specimens



Analysis of the following 11 types of HPV types was completed using clinical specimens

| Human infection HPV list      |
|-------------------------------|
| Human papillomavirus type 178 |
| Human papillomavirus type 136 |
| Human papillomavirus type 140 |
| Human papillomavirus type 154 |
| Human papillomavirus type 156 |
| Human papillomavirus type 179 |
| Human papillomavirus type 201 |
| Human papillomavirus type 49  |
| Human papillomavirus type 9   |
| Human papillomavirus type 92  |
| Human papillomavirus type 96  |

## PACKAGE COMPOSITION

| Package name      | Compositions                          | Package option           | Options                               |
|-------------------|---------------------------------------|--------------------------|---------------------------------------|
| Target Enrichment | Target capture Probe                  | Pooling method           | Single Reaction / Pre-capture Pooling |
| Standard          | Target Enrichment reagents            | Library Preparation kits | Standard Kit / EP-kit                 |
| All-In-One        | Library prep kit / Beads / Polymerase | Hybridization Enhancer   | Included / Not included               |